Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

FDA Initially Rejected AZ’s NDA for Farxiga

The US Food and Drug Administration (FDA) has issued a complete response letter to AstraZeneca regarding the supplemental New Drug Application for Farxiga (dapagliflozin), meaning that the governing b...

AstraZeneca to Appeal NICE’s Decision not to Recommend Tagrisso

astrazeneca
AstraZeneca will appeal NICE's decision not to recommend Tagrisso (osimertinib) for first-line non-small cell lung cancer (NSCLC). The drug is licensed in untreated locally-advanced or metastatic e...

EU CHMP Gives AstraZeneca Positive Opinion for DECLARE-TIMI 58 Cardiovascular Outcomes Data

AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the European marketing authorisation for Forxiga (dapaglifl...

EU CHMP Issued a Positive Opinion to Add a Self-Administration Option for Fasenra

AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option for Fasenra (benraliz...

AstraZeneca Announced positive Results from the Phase III Clinical Trials with Imfinzi

AstraZeneca announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet n...

Global Biopharm AstraZeneca to Invest $630m over 5 years in Korean R&D

astrazeneca
AstraZeneca PLC, a British-Swedish pharmaceutical company, will invest a total $630 million in South Korea’s biotech and healthcare sectors over five years starting next year, betting on the Korean go...

AstraZeneca’s Breztri Aerosphere Approved in Japan

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve symptoms of chronic...

EC Approved Lynparza as 1st-Line Maintenance Treatment for BRCA-Mutated Ovarian Cancer

astrazeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line...

AstraZeneca Presented Detailed Data from Calquence Phase III Clinical Trials

astrazeneca
AstraZeneca has presented detailed data showing that Calquence (acalabrutinib) significantly prolonged progression free survival (PFS) in patients with relapsed or refractory chronic lymphocytic leuka...

AstraZeneca and MSD’s Lynparza Doubled Progression-Free Survival in Pancreatic Cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced detailed results from the Phase III POLO trial at the 2019 American Societ...

US Court to Hear Aurobindo Pharma over Patent Infringement Allegations

court
Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg...

New Data Demonstrated the Effectiveness of AstraZeneca’s Symbicort Turbuhaler

astrazeneca
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammat...

AstraZeneca Announced Positive Results from the Phase III Trial of Calquence

AstraZeneca today announced positive results from the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a stat...

AstraZeneca Qternmet XR Approved in the USA

The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise t...

AstraZeneca and Transgene Agreed to Develop Viral Immunotherapies

astrazeneca
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies. Viral immunotherapy r...

AstraZeneca Announce Cooperation to Accelerate Drug Discovery

astrazeneca
AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disea...